Prevention of the cardiotoxic effects of adriamycin and daunomycin in the isolated dog heart.
D000818:Animals; D000900:Anti-Bacterial Agents / Q000009:adverse effects* / Q000037:antagonists & inhibitors / Q000378:metabolism; D001285:Atropine / Q000494:pharmacology; D001794:Blood Pressure / Q000187:drug effects; D002854:Chromatography, Paper; D003630:Daunorubicin / Q000009:adverse effects* / Q000378:metabolism; D004285:Dogs; D004492:Edetic Acid / Q000494:pharmacology; D004562:Electrocardiography; D005453:Fluorescence; D006321:Heart / Q000187:drug effects*; D006339:Heart Rate / Q000187:drug effects; D066298:In Vitro Techniques; D008238:Lysergic Acid Diethylamide / Q000494:pharmacology; D009206:Myocardium / Q000378:metabolism; D011433:Propranolol / Q000494:pharmacology; D012965:Sodium Chloride / Q000378:metabolism; D013997:Time Factors
D000900:Anti-Bacterial Agents; D012965:Sodium Chloride; D001285:Atropine; D008238:Lysergic Acid Diethylamide; D004492:Edetic Acid; D011433:Propranolol; D003630:Daunorubicin